UMMS Dedicates New Stoler Center for Advanced Medicine Cancer Facility

“We have marvelous doctors at UMMS, and they are working feverishly to develop cures and to develop access for the people who need it the most,” said Leonard Stoler, the Baltimore philanthropist whose $25 million gift put his family’s name on a new 14-story tower.

The University of Maryland Medical System on Monday hosted the dedication of the Roslyn and Leonard Stoler Center for Advanced Medicine in downtown Baltimore, the new home of its comprehensive cancer center, which opened to patients in late September.

The building, reported by umms.org, nearly doubles the footprint of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) and gives the University of Maryland Medical Center’s Downtown Campus a new main entrance at 22 S. Greene Street. Its glass front, lined with aluminum-covered mesh sails, shades patient rooms and cuts energy costs.

The stakes are clinical, not just architectural. UMGCCC is one of only two National Cancer Institute–designated comprehensive cancer centers in Maryland, and its patient volume has grown sharply over the past decade as more people arrive with complicated cancers needing multidisciplinary care and long follow-up.

The center treats 3,100 new patients a year, handles 62,000 outpatient visits and 1,400 inpatient admissions, and its executive director says the new tower raises inpatient and outpatient capacity by 40%.

“With this expansion, we will be able to provide the most advanced, integrated and compassionate care to cancer patients across Maryland and the region now and into the future,” said Taofeek K. Owonikoko, MD, PhD, UMGCCC’s executive director and the Kevin J. Cullen, MD Distinguished Professor of Oncology at the University of Maryland School of Medicine.

Building Boosts Cancer Treatment Capacity

  • A bigger building means shorter waits and more treatment slots: capacity for cancer patients rises 40% in both hospital and clinic settings.
  • The center already delivers cell-based therapies — about 150 bone marrow transplants and 100 CAR T-cell treatments for blood cancers each year — and the new space is built to expand them.
  • Patients treated at other University of Maryland hospitals can reach these trials through the University of Maryland Cancer Network, so the benefit extends beyond Baltimore.

Where the Therapies Are Heading

The clinical reason this tower matters is the shift toward personalized and cellular medicine. UMGCCC offers immunotherapies such as CAR T-cell therapy — in which a patient’s own T cells are engineered to attack their lymphoma or leukemia — and TIL therapy, which uses tumor-infiltrating lymphocytes harvested from a patient’s melanoma. It also delivers therapies tailored to a tumor’s genetic make-up, the approach clinicians call precision medicine.

“From advancing novel CAR T-cell therapies for aggressive lymphomas to being the first in the region to use innovative cell therapies for melanoma and rare sarcomas, our teams are helping transform cancer care,” said UMSOM Dean Mark T. Gladwin, MD, dean of the University of Maryland School of Medicine and executive vice president for medical affairs at the University of Maryland, Baltimore.

The center’s research record runs deep. The late Angela Brodie, PhD, developed aromatase inhibitors — drugs that block estrogen production to treat breast cancer — there, and the center invented the GammaPod, a radiation option for early-stage breast cancer.

In April, its doctors treated Maryland’s first adult sickle cell patient with gene therapy, a potentially curative one-time treatment for the inherited blood disorder. Annual research funding totals $186.2 million, and more than 400 clinical trials are open, with minority participation above 50% — well above the national average, as the literature on trial diversity shows.

Bert W. O’Malley, MD, president of the University of Maryland Medical Center, framed the building as an entry point to experimental medicine. “This is not just a building, but a concept – a new front door to academic medicine,” he said, adding that patients would have access to “FDA-approved therapies or experimental new treatments available in clinical trials.”

The Building by the Numbers

Measure Figure
Tower size 302,900 square feet, 14 stories
Private patient rooms 62
Infusion center spaces 48 private and semi-private
Capacity increase 40% inpatient and outpatient
New patients treated annually 3,100

The center’s six current floors hold 62 large private rooms on exterior walls with floor-to-ceiling windows, caregiver sleeping accommodations, an infusion center with 48 treatment spaces, a dedicated cancer pharmacy, exercise rooms for patients and respite rooms for staff.

A healing garden sits on the first floor, and most of the artwork is by Maryland artists. The upper four floors will fill in over the next three years with acute rehabilitation, general medicine and behavioral health.

What Opens Next

Over the next two to two-and-a-half years, the center plans a 24/7 urgent care service so cancer patients can be treated and released without admission, an outpatient area for growing bone marrow transplant volumes, a dedicated Phase I trials unit — where the very first human testing of experimental drugs happens — and an expanded apheresis unit and cell-processing laboratory.

As the cancer center vacates hospital space, crews will renovate the old first-floor outpatient clinic for University of Maryland Golisano Children’s Hospital to expand pediatric oncology.

The $25 million gift from Leonard Stoler, founder of the Len Stoler Automotive Group, anchors the philanthropy; his son Barry Stoler chairs UMGCCC’s Board of Advisors. The lobby honors the Greenebaum family, whose foundation gave $5.5 million earlier this year after three decades of support.

Former Governor Larry Hogan, treated there for aggressive lymphoma in 2015 and cancer-free since, told the dedication: “Thanks to the world-class care I received, I had the opportunity to continue serving the people of this great state.”

Clark Construction built the tower, designed by HDR using an immersive process that drew on input from staff, patients, families and the community; the construction began in May 2022.

New Center Offers Multidisciplinary Care

This is a facility opening, not a therapy, so no new contraindications apply. Referrals to UMGCCC can come through any University of Maryland Medical System hospital via its cancer network.

Dr. Owonikoko said the building was designed first and foremost for patients facing “some of the most challenging moments of their lives,” bringing multidisciplinary care and support services under one roof. For Stoler, the purpose reduces to a single word: “All that they come for is hope.”

References

  • University of Maryland Medical System news release: dedication of the Roslyn and Leonard Stoler Center for Advanced Medicine (November 2025)
  • National Cancer Institute comprehensive cancer center designation criteria (cancer.gov)

Treatment eligibility, including for cellular therapies and clinical trials, is determined by individual physicians based on each patient’s diagnosis and health status.

Photo of author

Health Desk

Health Desk at Archyde.

Ghostwriters From Invisible Scribes to Named Brands in Celebrity Publishing

Samsung Leak Suggests “Extremely Bezel-less” Display for Galaxy S27 Series